Cancer and Leukemia Group B Breast Committee: Decades of progress and plans for the future Journal Article


Authors: Hudis, C. A.; Winer, E. P.
Article Title: Cancer and Leukemia Group B Breast Committee: Decades of progress and plans for the future
Abstract: The Breast Committee of the Cancer and Leukemia Group B was formed in 1969 under the direction of James Holland. Initial studies examined combination chemotherapy for advanced disease. Although the committee has continued to conduct studies in patients with advanced disease, adjuvant therapy has been an even more important focus for the past 30 years. Over the past 20 years, studies have focused on optimization of chemotherapy through the testing of dose and schedule, the value of adding novel agents, and the role of biological agents. Current and future projects are aimed at exploiting and increasing our growing knowledge of the molecular biology of breast cancer by developing targeted therapies. © 2006 American Association for Cancer Research.
Keywords: leukemia; clinical trial; review; bevacizumab; cytotoxic agent; doxorubicin; fluorouracil; antineoplastic agents; paclitaxel; adjuvant therapy; chemotherapy; methotrexate; antineoplastic agent; neoplasms; breast cancer; cancer screening; cyclophosphamide; breast neoplasms; cancer research; cancer therapy; history, 20th century; societies, medical; medical oncology; tamoxifen; molecular biology; health care organization; lapatinib; clinical trials; fulvestrant
Journal Title: Clinical Cancer Research
Volume: 12
Issue: 11
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2006-06-01
Start Page: 3576s
End Page: 3580s
Language: English
DOI: 10.1158/1078-0432.ccr-06-9016
PUBMED: 16740788
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 4 June 2012" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Clifford Hudis
    905 Hudis
Related MSK Work